Hot AI Mandate: Canada-based Family Office Looking for Big-data or AI-related Opportunities in Healthcare

11 May

A single family office founded in 2009 and based in Toronto is now looking to expand into the healthcare sector and plans to initially invest approximately $10M into seed-stage deals in the healthcare space and may potentially reserve another pool of capital for additional healthcare investments in the future. The firm has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.

Within healthcare, the firm is focused on the medtech, diagnostic and health IT space. The firm is particularly interested in newly created or accessible markets such as leveraging smart phones, big data/data mining and AI for healthcare purposes. The firm is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.

The firm seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The firm typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot AI Mandate: US-based VC Invests in Early-stage AI-enabled Platforms in Healthtech

11 May

Founded in 2006, a specialized healthcare and life sciences investment firm with over a half-billion dollars in capital under management will close their fourth fund in 2021. The firm invests in early-stage companies (Seed/Series A) developing innovative new medical technologies, biotechnologies, and digitally-enabled healthcare services. The firm generally invests $4-8 million of equity capital per round and up to $10-20 million over the investment life. The firm is actively investing and will make 3-5 investments in 2021.The firm invests nationally and has offices in Austin, TX, and Boston, MA.

The firm is currently looking for companies developing Medical Devices, Therapeutics, Diagnostics, and Healthcare IT products. For medical devices and therapeutics, the firm is open to the full spectrum of subsector and indication and will consider companies developing orphan indications. In HealthTech, the firm is interested in AI-enabled clinical/diagnostic/workflow platforms but will also consider other companies that fall into the broader Healthcare IT space as well, including mobile health companies developing consumer-facing apps. They will consider companies with proprietary platform technologies as well as single/multiple asset companies.

As an early-stage investor, the firm invests almost exclusively in pre-revenue companies, with significant ownership opportunities. They look for experienced management teams, help build the team, and require a seat on the company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Partnering at Digital RESI June

6 May

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Digital Redefining Early Stage Investments (RESI), June 8-10, is fast-approaching and early bird rates end tomorrow! Sign up by Friday, May 5 to save $50 on registration to take advantage of the RESI partnering system which enables early-stage fundraising executives to connect with investors and strategic partners that are a fit for their product and stage of development.

Digital RESI stands apart from other virtual partnering conferences in many ways, including its content and resources, but most importantly, its partnering platform. The RESI partnering platform is a user-friendly system designed to take out the guesswork so investors, strategic partners, and fundraising entrepreneurs can easily find and book meetings with those that are a best fit based on sector, indication, product, development phase, and more.

The Digital RESI partnering platform opens May 17, providing registered attendees three weeks to set up their company profiles and start searching for potential partners and book meetings to optimize their time during the conference. Prior to the launch of partnering, Life Science Nation (LSN) highlights several free tutorials and webinars instructing how to use the platform efficiently, as well as tips on how to stand out when requesting meetings.

Click the date(s) below to register for the FREE Strategies for Successful Partnering workshops:

Check out more free partnering resources from LSN:

Stories for a New Age

6 May

By Rory McCann, Marketing Manager & Conference Producer, LSN

When LifeBio Founder and CEO, Beth Sanders started telling stories, she knew how influential they could be. Today, patients and healthcare providers are using LifeBio’s storytelling platform to connect, decrease loneliness, and promote better care and overall wellness.

LifeBio was a winner at the March Innovator’s Pitch Challenge at Longevity, Health & Innovation (now RESI Longevity). Registration for RESI Longevity (September 16-17) is now open at super early bird rates until July 23, and applications for the next Innovator’s Pitch Challenge are open!

Listen to our conversation with Beth on the origin and mission of LifeBio, and how stories are having a strong impact on today’s seniors and the healthcare system.

Tech Hubs Making the Difference for Entrepreneurs

6 May

By Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

It is hard to believe, but even during these challenging times, funding and deal-making in the life sciences has not slowed down, and in some sectors, has accelerated. Life Science Nation (LSN) has contributed to this momentum by providing a digital venue for the different players to connect and build relationships to move the needle.

LSN sees that Tech Hubs—incubators, accelerators, life science clusters, etc.—from around the world are making a huge difference in preparing entrepreneurs for success in their projects and have seen a fantastic opportunity to collaborate closely with these groups and their constituent companies. It’s a win-win-win. By facilitating access to resources, including the Investor Database, Redefining Early Stage Investments (RESI) conference series, Innovator’s Pitch Challenge, and industry expertise, LSN is helping entrepreneurs meet the investors and strategic partners they need to meet and save money at the same time.

LSN is currently offering two programs to accelerate Tech Hub involvement and help constituents get funded:

  1. 50% discount on any RESI conference registration for early-stage constituent companies from participating Tech Hubs
  2. Group Fundraising Package ($1,500 per company) for Tech Hubs including:
    1. 3-month access to the Investor Database
    2. Registration at RESI
    3. Participation in the Innovator’s Pitch Challenge

If your Tech Hub is looking for ways to add value to fundraising constituents, connect with the LSN business development team to see which offerings best fit your needs and the companies in your community. LSN shares the mission of global Tech Hubs in seeing promising technologies advance from the lab to the clinic, and into the hands of providers and their patients.

Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International & MA (USA) West Coast (USA) East Coast (USA) Midwest (USA) & Canada 
Greg Mannix
Vice President International Business Development
Schedule a call with me!		 Candice He
 Global Investment Strategist
Schedule a call with me!		 Ashley Zborowski
Director of Business Development
Schedule a call with me!		 Elizabeth Murphy
Manager of Business Development
Schedule a call with me!

Hot Investor Mandate: Publicly Traded Diagnostics Company with USA & China Operations Seeks to Partner or Acquire Early-Stage Oncology Diagnostics Companies

6 May

A publicly NASDAQ-traded diagnostics company with operations in China and the United States specializes in pre-cancer and cancer screening based on biophysical properties. The firm is looking to partner or acquire a majority share in early stage companies in the diagnostics space. While the firm is looking to be the majority stakeholder in these companies, the firm is most interested in continuing a partnership/joint venture with these startups, as opposed to a full acquisition. The firm is willing to partner globally.

The firm is interested in diagnostics companies only. Within diagnostics, the firm is interested in two types of partnerships. First, the firm is seeking oncology diagnostics that use genetic or biomarker identification of specific cancer types that can be paired with their technology, meshing the specific genetic/biomarker for these cancers with the biophysical anomalies they detect. Additionally, the firm is also looking to partner with companies in the oncology space that are seeking to expand to China and can take advantage of the firm’s existing infrastructure. For these partnerships, the firm is interested in all forms of diagnostics in all indications.

The firm is looking to acquire at least a 51% stake in the companies with which they are partnering, but is open to any structures that are advantageous for all parties. As a partner, the firm has facilities in place for any additional research or clinical tests needed to help companies reach commercialization in the United States, as well as the ability to help with distribution, especially in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Firm Interested in Pre-Seed to Series A Medical Devices, Diagnostics, and AI-Related Companies in North America

6 May

A venture capital firm based in the USA makes around 1/3 of its investments in industry tech mainly focusing on digital transformation within traditional sectors, second 1/3 in enterprise tech including both SaaS and network technology, and the last 1/3 in healthcare , including AI in healthcare and medical devices.

The firm typically invests $1M-$2M initial check per company,  and reserve 2/3 of the fund for pro rata. The firm prefers to lead the round and also open to co-investment. The firm typically makes 7-10 new investments per year, and only focuses on companies based in North America (USA & Canada). Furthermore, the firm has a considerable value-add in supporting companies leveraging their former entrepreneur and operator experience, and their CXO network which includes over 30 executives from Fortune 1000 companies.

The firm is open to all subsectors of AI in healthcare, diagnostics and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed and pre-Series A stage.

The firm does not have a particular management team requirement, as it primarily assesses the technology itself. If leading the round, the firm will take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →